Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)

NCT02258152 is registered in ClinicalTrials.gov with Biotie Therapies Inc. as lead sponsor.

NCT NCT02258152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02258152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Lead sponsor
Biotie Therapies Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 22, 2014
Completion date
October 3, 2017
Enrollment
82 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease dementia (pdd)